

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Nguyen, Mindie, MD, MAS

eRA COMMONS USER NAME (credential, e.g., agency login): NGUYEN.MINDIE

POSITION TITLE: **Professor of Medicine, Gastroenterology, Hepatology and Liver Transplant, and by courtesy, of Epidemiology and Population Health, Stanford University Medical Center, Palo Alto, CA**

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
University of California, Irvine, CA	BS	06/1988	Biological Sciences
University of California, San Diego, CA	MD	06/1992	Medicine
University of California, San Francisco, CA	MAS	06/2004	Clinical Research

Personal Statement

A. As a physician investigator practicing general and transplant hepatology, my research is focused on the epidemiology and clinical management of viral hepatitis B and C (HBV and HCV), non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC), particularly cancer prevention, linkage to care, ethnic influence and health disparities. I conduct clinical outcomes studies, health economics studies, clinical trials, epidemiological studies, and translational research in viral hepatitis, NAFLD and HCC (<https://profiles.stanford.edu/mindie-nguyen>). As a clinician, I see patients 3 full days a week at the Stanford general liver clinic, liver transplant clinic, and liver outreach clinics in our surrounding communities. In addition, I have an active research program with over 10 research coordinators/research associates with several holding MD or PhD degrees and 30 other students, residents, fellows, postdocs, visiting scholars and junior to mid level faculty at Stanford University as well as other institutions in the United States and overseas (<https://med.stanford.edu/nguyenlab>). I have mentored close to 150 mentees from high school students, undergrads, MPH/MS and PhD students in Epidemiology, medical students, residents/fellows, research postdocs, and faculty at Assistant and Associate Professor rank. Our program focuses on the natural history and treatment outcomes of HCC and the major diseases that cause HCC such as HBV, HCV, and NAFLD.

Over the past 20 years, I have completed projects which I would like to highlight, as follows:

The establishment of several large local registries/cohorts and a biobank: A HBV registry/cohort with over 5,500 patients, an HCV registry/cohort with over 10,000 patients, a NAFLD registry/cohort of over 3000 patients, cirrhosis (of all etiologies) registry/cohort of over 11,000 patients, an HCC registry/cohort of over 2500 patients, and a biobank with serum, plasma and/or DNA samples of over 1200 patients at Stanford University Medical Center and local collaborating community clinical centers.

The establishment of national and international registries/cohorts with investigators from more than 50 major academic institutions in the U.S., South America (Argentina), Europe (Spain, Austria, Romania), and Asia Pacific region (Taiwan, Hong Kong, China, Korea, Japan, New Zealand, Singapore), with whom I have established and led several clinical consortia (HBV Natural History and Treatment Outcomes Registry with currently over 30,000 patients, HCC Epidemiology Consortium with over 14000 patients, and HCV Treatment Outcome Registry of over 13,000 patients, and NAFLD of over 10000 patients).

The utilization of large epidemiologic or real-world national and international databases such as Truven, Optum, NHANES, SEER, CDC WONDER, NDI, and UK Biobank to investigate population level research questions and to support trend and forecasting analysis for important liver diseases such as HCC and NAFLD.

I have also served as *lead-PI* for 6 multicenter observational and therapeutic clinical trials and as member of the Trial Guidance and Publication Committee for 2 multinational therapeutic clinical trials.

B. Positions, Scientific Appointments, and Honors

Employment Positions

1992-1995 Intern and Resident in Internal Medicine, University of California, San Diego, CA
1995-1996 Chief Resident in Internal Medicine, University of California, San Diego, CA
1995-1997 Clinical Instructor, Internal Medicine, University of California, San Diego, CA
1996-1999 Staff Physician, Internal Medicine/Hospital-Based Specialist, Kaiser Permanente, CA
1999-2002 Fellow and Chief Fellow in GI & Hepatology, Stanford University, Palo Alto, CA
2002-2004 Clinical Instructor & Staff Physician, GI & Hepatology, Stanford University, CA
2002-2010 Consultant Physician, GI, Veterans Administration Medical Center, Palo Alto, CA
2004-2005 Clinical Assistant Professor of Medicine, GI & Hepatology, Stanford University, PA, CA
2005-2012 Assistant Professor of Medicine, GI & Hepatology, Liver Transplant Program, SUMC, CA
2012-2017 Associate Professor of Medicine, GI & Hepatology, Liver Transplant Program, SUMC, CA
2017- Professor of Medicine, GI & Hepatology, Liver Transplant Program, Stanford Univ. MC, CA
2020- Professor of Epidemiology and Population Health (by courtesy), Stanford Univ. MC, CA

Scientific and Professional Appointments

2008- Editorial Board, Digestive Diseases and Sciences
2011- Editorial Board, Gastroenterology
2017-2019 Editorial Board, Hepatology
2018- International Advisory Board, Lancet Gastroenterology and Hepatology
2018-2020 International Editorial Board, Alimentary Pharmacology and Therapeutics
2019-2020 Chair, Hepatitis B SIG, American Association for the Study of Liver Disease (AASLD)
2019- Governing Council and Treasurer, International Association for the Study of Liver Diseases (IASL)
2019- Research Award Panel, American Gastroenterological Association (AGA)
2019- Practice Management Committee, American College of Gastroenterology (ACG)
2019- Practice Guideline Committee, American Association for the Study of Liver Disease (AASLD)

Honors

1984-1988 Southland Scholar Award, University of California, Irvine
1985-1988 Lockheed Management Award, University of California, Irvine
1988 Magna Cum Laude, University of California, Irvine
1995 Excellence in Teaching Award, University of California, San Diego, CA
1995 Chief Resident in Medicine, University of California, San Diego
1999 AASLD/Schering Advanced Hepatology Research Fellow Award
2001 Chief Fellow in GI & Hepatology, Stanford University Medical Center, Palo Alto, CA
2013 Cardinal Free Clinic Physician Service Award, Stanford, CA
2013 Franklin Edbaugh Advising Award for Faculty, Stanford University School of Medicine
2015 Stanford Asian American Faculty Awards, Stanford University, Stanford, CA
2015 Divisional Teaching Award, Department of Medicine, Stanford University MC, Palo Alto
2020 The Professor Mindie H. Nguyen Award in Clinical Research for Young Investigator (4 a year), AASLD Foundation Ward

C. Contributions to Science (selected recent work from 259 original published research articles, 100+ book chapters/ reviews/editorials/letters).

1. **For HCC**, I have focused on screening, diagnosis, and prevention of hepatocellular carcinoma (HCC), with special attention to the racial disparities and novel biomarkers. More recent work:
 - a. Estevez J, Yang JD, Leong J, Nguyen P, Giama NH, Lee M-H, Cheung R, Roberts L, Schwartz M, Nguyen MH. Clinical features associated with survival outcome in African-American patients with hepatocellular carcinoma. *Am J Gastroenterol.* **2019** Jan;114(1):80-88. PMID: 30333542.
 - b. Hsu YC, Wong GL, Chen CH, Peng CY, Yeh ML, Cheung KS, Toyoda H, Huang CF, Trinh H, Xie Q, Enomoto M, Liu L, Yasuda S, Tanaka Y, Kozuka R, Tsai PC, Huang YT, Wong C, Huang R, Jang TY,

- Hoang J, Yang HI, Li J, Lee DH, Takahashi H, Zhang JQ, Ogawa E, Zhao C, Liu C, Furusyo N, Eguchi Y, Wong C, Wu C, Kumada T, Yuen MF, Yu ML, Nguyen MH. Tenofovir versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. **Am J Gastroenterol** 2020 Feb;115(2):271-280. PMID: 31634265
- c. Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, Hai H, Thuy LTT, Hosaka T, Sezaki H, Borghi JA, Cheung R, Enomoto M, Nguyen MH. The impact of tenofovir disoproxil fumarate (TDF) versus entecavir (ETV) on chronic hepatitis B virus infection related hepatocellular carcinoma: A systemic review and meta-analysis. **Lancet Gastroenterol Hepatol.** 2020 Dec;5(12):1039-1052. PMID: 33007228
 - d. Tran S, Jeong D, Henry L, Cheung RC, Nguyen MH. Initial Evaluation, Monitoring, and Surveillance of Chronic Hepatitis B in Routine Practice: A Nationwide US Study. **Am J Gastroenterol** 2021 Apr 29. doi: 10.14309/ajg.0000000000001271. Online ahead of print. PMID: 33927125
 - e. **Chen VL**, Yeh ML, Yang JD, Leong J, Huang DQ, Toyoda H, Chen YL, Guy J, Maeda M, Tsai PC, Huang CF, Yasuda S, Le AK, Dang H, Giama NH, Ali HA, Zhang N, Wang X, Jun DW, Tseng CH, Hsu YC, Huang JF, Dai CY, Chuang WL, Zhu Q, Dan YY, Schwartz M, Roberts LR, Yu ML, **Nguyen MH**. Effects of cirrhosis and diagnosis scenario in metabolic-associated fatty liver disease-related hepatocellular carcinoma. **Hepatol Comm** 2020 Sep 24;5(1):122-132. PMID: 33437906
2. **For HBV**, I have examined the epidemiology of disease and linkage to care systems. In prospective cohorts, I have studied HBV treatment response and effects on HCC. More recent work:
- a. Yeo YH, Ho HJ, Yang HI, Tseng TC, Hosaka T, Trinh HN, Kwak MS, Park YM, Fung JYY, Buti M, Rodríguez M, Treeprasertsuk S, Preda CM, Ungtrakul T, Charatcharoenwitthaya P, Li X, Li J, Zhang J, Le MH, Wei B, Zou B, Le A, Jeong D, Chien N, Kam L, Lee CC, Riveiro-Barciela M, Istratescu D, ... Tanwandee T, Kobayashi M, Suzuki F, Yuen MF, Lee HS, Kao JH, Lok AS, Wu CY, Nguyen MH. Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. **Gastroenterology** 2019 Feb;156(3):635-646. PMID: 30342034
 - b. Nguyen MH, Burak Ozbay A, Liou I, Meyer N, Gordon SC, Dusheiko G, Lim JK. Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B. **J Hepatol** 2019 Jan;70(1):24-32. PMID:30287341
 - c. Le MH, Yeo YH, Cheung R, Henry L, Lok AS, Nguyen MH. Chronic hepatitis B prevalence among foreign-born and US-born adults in the United States, 1999-2016. **Hepatology** 2020 Feb;71(2):431-443. PMID:31228279.
 - d. Ramrakhiani NS*, Chen VL*, Le M, Yeo YH, Barnett SD, Waljee AK, Zhu J, Nguyen MH. Optimizing Hepatitis B Virus Screening in the United States Using a Simple Demographics-Based Model. **Hepatology** 2021 Sep 8. doi: 10.1002/hep.32142. Online ahead of print. PMID: 34496066
 - e. Ye Q, Kam LY, Yeo YH, Dang N, Huang DQ, Cheung R, Nguyen MH. Substantial gap in assessment and treatment of chronic hepatitis B (CHB) patients in the United States. **J Hepatol** 2021Aug 30:S0168-8278(21)02014-6. Online ahead of print. PMID: 34474097
3. **For HCV**, my research contributions have focused on the understudied ethnic populations and low resource settings. I have studied the different HCV genotypes among Asian populations to better understand associated risk factors in this population.
- a. Jayasekera CR, Barry M, Roberts LR, Nguyen MH. Treating Hepatitis C in Lower Income Countries. **N Engl J Med.** 2014;370:1869-1871. PMID: 24720680.
 - b. Gane E, Kowdley KV, Pound D, Stedman CA, Davis M, Etzkorn K, Gordon SC, Bernstein D, Everson G, Rodriguez-Torres M, Tsai N, Khalid O, Yang JC, Lu S, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Tong M, Chung RT, Beavers K, Poulos JE, Kwo PY, Nguyen MH. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients with HCV Genotype 2, 3, 4, or 6 Infections in an Open-label, Phase 2 Trial. **Gastroenterology** 2016;151:902-909. PMID: 2748603.
 - c. Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, Iio E, Lubel J, Wang W, Wei B, Ide T, Preda CM, Conti F, Minami T, Bielen R, Sezaki H, Barone M, Kolly P, Chu PS, Virlogeux V, Eurich D, Henry L, Bass MB, Kanai T, Dang S, Li Z, Dufour JF, Zoulim F, Andreone P, Cheung RC, Tanaka Y, Furusyo N, Toyoda H, Tamori A, Nguyen MH. Sustained virologic response to direct-acting antiviral therapy in

patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. *J Hepatol*. 2019 Sep;71(3):473-485. PMID: 31096005

- d. Dang H, Yeo YH, Yasuda S, Huang CF, Iio E, Landis C, Jun DW, Enomoto M, Ogawa E, Tsai PC, Le A, Liu M, Maeda M, Nguyen B, Ramrakhiani N, Henry L, Cheung R, Tamori A, Kumada T, Tanaka Y, Yu ML, Toyoda H, Nguyen MH. HCV cure by interferon-free direct acting antiviral therapy are associated with increased survival in patients with HCV-related HCC. *Hepatology* 2020 Jun;71(6):1910-1922. PMID: 31610027
 - e. Ogawa E, Toyoda H, Iio E, Jun DW, Huang CF, Enomoto M, Hsu YC, Haga H, Iwane S, Wong G, Lee DH, Tada T, Liu CH, Chuang WL, Hayashi J, Cheung R, Yasuda S, Tseng CH, Takahashi H, Tran S, Yeo YH, Henry L, Barnett SD, ... Kao JH, Eguchi Y, Ueno Y, Tamori A, Furusyo N, Yu ML, Tanaka Y, Nguyen MH; Real-World Evidence from the Asia Liver Consortium Investigators for HCV (REAL-C) .HCV Cure Rates are Reduced in Patients with Active but not Inactive Hepatocellular Carcinoma- A Practice Implication. *Clin Infect Dis*. 2020 Dec 31;71(11):2840-2848. PMID: 31777940
- 4. For NAFLD**, my group studies the epidemiology and natural history of NAFLD, with focuses on ethnic differences and interaction between NAFLD with viral hepatitis B and C. More recent work:
- a. Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, Wu Y, Kam LY, Ji F, Li X, Chien N, Wei M, Ogawa E, Zhao C, Wu X, Stave CD, Henry L, Barnett S, Takahashi H, Furusyo N, Eguchi Y, Hsu YC, Lee TY, Ren W, Qin C, Jun DW, Toyoda H, Wong VW, Cheung R, Zhu Q, Nguyen MH. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2019 May;4(5):389-398. PMID: 30902670
 - b. Ye Q, Zou BY, Yeo YH, Li J, Huang DQ, Wu YK, Yang HL, Liu CL, Kam LY, Tan XX, Chien N, Trinh S, Henry L, Stave CD, Hosaka T, Cheung, Nguyen MH. Global prevalence, incidence and outcome of non-obese or lean N RCAFLLD: A meta-analysis of 93 studies and 10,576,383 persons. *Lancet Gastroenterol Hepatol* 2020 Aug;5(8):739-752. PMID: 32413340
 - c. Li J, Le MH, Barakat MT, Cheung RC, Nguyen MH. The Changing Epidemiology of Liver Disease Among United States Children and Adolescents from 1999-2016. *Am J Gastroenterol* 2021. Jul 30. doi: 10.14309/ajg.0000000000001386. Online ahead of print. PMID: 34328446
 - d. Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. *Clin Gastroenterol Hepatol* 2021 May 22:S1542-3565(21)00567-X. doi: 10.1016/j.cgh.2021.05.029. Online ahead of print. PMID: 34033923
 - e. Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, Ye Q, Huang DQ, Zhao C, Zhang J, Liu C, Chang N, Xing F, Yan S, Hui WZ, Sook Yee NT, Mayumi M, Liu X, Liu C, Rui F, Yang H, Yang Y, Jin R, Le RH, Xu Y, Le DM, Barnett S, Stave CD, Cheung R, Zhu Q, Nguyen MH. 2019 Global NAFLD Prevalence – As Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol*. 2021 Dec 7:S1542-3565(21)01280-5. doi: 10.1016/j.cgh.2021.12.002. Online ahead of print. PMID: 34890795
- 5. For cirrhosis**, we study the natural history and management of patients with cirrhosis. More recent work:
- a. Yeo YH, Hwang J, Jeong D, Dang N, Kam LY, Henry L, Park H, Cheung R, Nguyen MH. Surveillance of Patients with Cirrhosis Remains Suboptimal in the United States. *J Hepatol* 2021 May 6:S0168-8278(21)00307-X. doi: 10.1016/j.jhep.2021.04.042. Online ahead of print. PMID: 33965477
 - b. Tantai X, Liu Y, Yeo YH, Praktijnjo M, Mauro E, Hamaguchi Y, Engelmann C, Zhang P, Jeong JY, van Vugt JLA, Xiao H, Deng H, Gao X, Ye Q, Zhang J, Yang L, Cai Y, Liu Y, Liu N, Li Z, Han T, Kaido T, Sohn JH, Strassburg C, Berg T, Trebicka J, Hsu YC, IJzermans JNM, Wang J, Su GL, Ji F, Nguyen MH. The effect of sarcopenia on survival for patients with liver cirrhosis: A systematic review and meta-analysis. *J Hepatol* 2021 Nov 13:S0168-8278(21)02174-7. doi: 10.1016/j.jhep.2021.11.006. PMID: 34785325
 - c. Audrey Ha, Michael Le, Linda Henry, Yee Hui Yeo, Ramsey Cheung, **Mindie Nguyen**. County-level Variation in Cirrhosis-related Mortality in the US, 1999-2019. *JAMA NO* 2022 Feb 1;5(2):e2146427. *In press*.

D. Scholastic Performance N/A